WallStreetZenWallStreetZen

NASDAQ: AMRN
Amarin Corp PLC Stock

$0.96-0.06 (-5.88%)
Updated Apr 12, 2024
AMRN Price
$0.96
Fair Value Price
$1.53
Market Cap
$393.01M
52 Week Low
$0.65
52 Week High
$1.49
P/E
-6.38x
P/B
0.71x
P/S
1.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$306.91M
Earnings
-$59.11M
Gross Margin
53.9%
Operating Margin
-17.48%
Profit Margin
-19.3%
Debt to Equity
0.51
Operating Cash Flow
$7M
Beta
1.19
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AMRN Overview

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Zen Score

Industry Average (43)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AMRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AMRN ($0.96) is undervalued by 37.5% relative to our estimate of its Fair Value price of $1.53 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AMRN ($0.96) is significantly undervalued by 37.5% relative to our estimate of its Fair Value price of $1.53 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AMRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AMRN due diligence checks available for Premium users.

Be the first to know about important AMRN news, forecast changes, insider trades & much more!

AMRN News

Valuation

AMRN fair value

Fair Value of AMRN stock based on Discounted Cash Flow (DCF)
Price
$0.96
Fair Value
$1.53
Undervalued by
37.31%
AMRN ($0.96) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AMRN ($0.96) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AMRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AMRN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.38x
Industry
153.83x
Market
42.64x

AMRN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.71x
Industry
5.82x
AMRN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AMRN's financial health

Profit margin

Revenue
$74.7M
Net Income
-$5.8M
Profit Margin
-7.7%
AMRN's Earnings (EBIT) of -$53.66M... subscribe to Premium to read more.
Interest Coverage Financials
AMRN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$831.7M
Liabilities
$279.6M
Debt to equity
0.51
AMRN's short-term assets ($724.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMRN's short-term assets ($724.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMRN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AMRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$645.0k
Investing
-$71.0M
Financing
$83.0k
AMRN's operating cash flow ($6.88M)... subscribe to Premium to read more.
Debt Coverage Financials

AMRN vs General Drug Manufacturer Stocks

TickerMarket Cap1d %P/EP/B
AMRN$393.01M-6.18%-6.38x0.71x
SCLX$221.03M+2.31%-1.04x-1.28x
OGN$4.46B-4.54%4.35x-63.73x
GRFS$4.51B-1.35%19.47x0.68x
BIIB$28.81B-2.70%24.71x1.95x

Amarin Stock FAQ

What is Amarin's quote symbol?

(NASDAQ: AMRN) Amarin trades on the NASDAQ under the ticker symbol AMRN. Amarin stock quotes can also be displayed as NASDAQ: AMRN.

If you're new to stock investing, here's how to buy Amarin stock.

What is the 52 week high and low for Amarin (NASDAQ: AMRN)?

(NASDAQ: AMRN) Amarin's 52-week high was $1.49, and its 52-week low was $0.65. It is currently -35.56% from its 52-week high and 47% from its 52-week low.

How much is Amarin stock worth today?

(NASDAQ: AMRN) Amarin currently has 410,671,800 outstanding shares. With Amarin stock trading at $0.96 per share, the total value of Amarin stock (market capitalization) is $393.01M.

Amarin stock was originally listed at a price of $312.00 in Dec 31, 1997. If you had invested in Amarin stock at $312.00, your return over the last 26 years would have been -99.69%, for an annualized return of -19.95% (not including any dividends or dividend reinvestments).

How much is Amarin's stock price per share?

(NASDAQ: AMRN) Amarin stock price per share is $0.96 today (as of Apr 12, 2024).

What is Amarin's Market Cap?

(NASDAQ: AMRN) Amarin's market cap is $393.01M, as of Apr 14, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Amarin's market cap is calculated by multiplying AMRN's current stock price of $0.96 by AMRN's total outstanding shares of 410,671,800.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.